| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Department of Cardiology, University of Heidelberg, 69115 Heidelberg, Germany
A NUMBER OF
VASCULAR PATHOLOGIES leads to an alteration of the physiology of
endothelial cells, which is generally described as endothelial
dysfunction. Endothelial dysfunction is found in basically all known
major risk factors of atherosclerosis such as hypercholesterolemia,
nicotin abuse, hypertension, and diabetes as well as in the manifest of
atherosclerosis (1, 4, 10, 16, 30, 35, 40). Furthermore,
endothelial dysfunction is a hallmark of many cardiac and coronary
pathologies, including ischemia-reperfusion injury,
inflammation, unstable angina, and acute myocardial infarction
(6, 12, 33, 38). Endothelial dysfunction is defined as an
attenuated response of coronary vessels to endothelium-dependent
vasodilators such as acetylcholine. It affects large conductance
vessels as well as the coronary microcirculation (16, 40).
Because endothelial dysfunction seems to be a general reaction of
vessels to a variety of pathophysiological stimuli, it offers a very
attractive target for a therapeutic approach. This, however, requires a
thorough understanding of the underlying pathology.
The reduction of endothelium-dependent vasodilation is mainly induced
by a decreased bioavailability of the endothelium-dependent vasodilator
nitric oxide (NO) and an increase in the activity of toxic oxygen free
radicals such as the superoxide anion O Recently, several findings have been made that lead to the hypothesis
that tetrahydrobiopterin could be a new and an effective therapeutical
option in the treatment of endothelial dysfunction. On the basis of
biochemical observations, these findings have been confirmed in in
vitro experiments with isolated cells and isolated perfused vessels and
have finally been transferred to clinical studies.
There is a close relationship between the availability of the NO
synthase cofactor tetrahydrobiopterin and NO synthesis in both
endothelial and vascular smooth muscle cells (5, 8). Biochemically, NO synthase consists of a flavin-containing reductase domain, a heme-containing oxygenase domain, and a regulatory
calmodulin-binding sequence. In addition to calcium/calmodulin, NO
synthase requires tetrahydrobiopterin as a cofactor. The precise role
of tetrahydrobiopterin in the formation of NO is still unclear, but it
is likely to have an effect as an allosteric factor and/or as a redox
cofactor (11, 17). In addition, tetrahydrobiopterin
stabilizes NO synthase and facilitates the binding to
L-arginine (29). Figure
1 schematically demonstrates the role of
tetrahydrobiopterin in the production of NO.
INTRODUCTION
TOP
INTRODUCTION
BIOCHEMICAL AND CELL CULTURE...
DATA FROM EXPERIMENTS IN...
CLINICAL DATA
CONCLUSIONS
REFERENCES
BIOCHEMICAL AND CELL CULTURE DATA
TOP
INTRODUCTION
BIOCHEMICAL AND CELL CULTURE...
DATA FROM EXPERIMENTS IN...
CLINICAL DATA
CONCLUSIONS
REFERENCES
View larger version (28K):
[in a new window]
Fig. 1.
Under physiological conditions, following binding of
tetrahydrobiopterin (BH4) to the oxidase domain of nitric oxide (NO)
synthase (NOS), the enzyme is activated and generates NO and
L-citrulline from L-arginine and
O2. NO diffuses rapidly to the underlying smooth muscle
cells leading to relaxation through an increase of cGMP levels.
The intracellular levels of tetrahydrobiopterin are controlled by the
generation of both NO and superoxide (9, 27). Under conditions when intracellular concentration of tetrahydrobiopterin is
reduced, NO synthase generates superoxide anions instead of NO
(2, 32, 36). Under physiological conditions, there is a
balance between endothelial production of NO and oxygen-derived free
radicals. However, in the presence of vascular risk factors or
atherosclerosis, there is a shift of this balance toward the production
of toxic oxygen-derived free radicals (22; Fig.
2). The underlying reason for the
decreased availability of tetrahydrobiopterin in endothelial
dysfunction has not yet been clarified. In endothelial cells, under
physiological conditions tetrahydrobiopterin is synthesized from GTP
via a de novo pathway by the rate-limiting enzyme GTP cyclohydrolase I
(17). Alternatively, the synthesis of tetrahydrobiopterin can occur via a so-called salvage pathway with sepiapterin as a
substrate, independent from GTP cyclohydrolase I. Therefore, it can be
speculated that a reduced expression of GTP cyclohydrolase I may be
involved in the pathology of decreased generation of tetrahydrobiopterin in atherosclerosis as has recently been shown in
coronary endothelial cells of diabetic rats (19). The
significance for human vessels needs to be clarified in further
investigations.
|
Another possible explanation for the reduced availability of tetrahydrobiopterin in endothelial dysfunction is an influence of toxic radicals, which induce an alteration in cellular redox state, on the biochemistry of tetrahydrobiopterin. Toxic radicals may interact with the role of tetrahydrobiopterin as a redox agent in the synthesis of NO, affect the biosynthesis of tetrahydrobiopterin via depletion of NADPH (21), and/or prevent the recycling of tetrahydobiopterin, which is supposed to occur via flavin nucleotides (29). Furthermore, there is evidence that oxidized tetrahydrobiopterin derivatives such as 7,8-dihydrobiopterin enhance superoxide formation from endothelial NO synthase (37). Finally, it has been shown that tetrahydrobiopterin can rapidly be oxidized by peroxynitrite. This implies that if tetrahydrobiopterin levels are decreased, a concomittant increase of NO synthase-dependent generation of superoxide and peroxynitrite induces a further reduction of tetrahydrobiopterin availability (20).
An increase of both endogenous tetrahydrobiopterin production and NO synthesis through application of sepiapterin has previously been demonstrated (5, 8, 28). Furthermore, it has been shown that endothelial cell damage can be prevented by pretreatment with sepiapterin via increased intracellular levels of tetrahydrobiopterin (13).
| |
DATA FROM EXPERIMENTS IN ISOLATED VESSELS |
|---|
|
TOP
INTRODUCTION
BIOCHEMICAL AND CELL CULTURE...
DATA FROM EXPERIMENTS IN...
CLINICAL DATA
CONCLUSIONS
REFERENCES
|
|---|
On the basis of the findings from experiments in cell-free media and in isolated cells, the effect of substitution with tetrahydrobiopterin or sepiapterin on endothelial dysfunction was investigated in isolated perfused vessels. We examined the influence of different tetrahydrobiopterin derivatives in isolated coronary resistance arteries from dogs, pigs, and humans. In these vessels, endothelial dysfunction was induced by either 1)ischemia-reperfusion (canine vessels) or 2) atherosclerosis following application of a cholesterol-rich diet for 4 mo (porcine vessels) or atherosclerosis resulting from the presence of coronary risk factors and confirmed by coronary angiography (human vessels). In all these pathologies, the responses of vessels to different species-dependent and endothelium-dependent agonists (dogs: calcium iononophore A-23187, serotonin, substance P; pigs: histamine, serotonin, substance P; humans: acetylcholine, histamine, serotonin) were significantly reduced. In contrast, the responses to an endothelium-independent vasodilator (sodium nitroprusside) were unaltered, indicating endothelial dysfunction. Additionally, the responses of vessels from nonischemic, nonatherosclerotic control hearts from the different groups to the endothelium-dependent vasodilators were normal.
In the dog experiments, following ischemia-reperfusion substitution of either sepiapterin or methyltetrahydropterin, a synthetic tetrahydrobiopterin, significantly improved endothelial function of coronary resistance arteries from the ischemic area as demonstrated by normalization of the effect of the different endothelium-dependent agonists. In contrast, the response of vessels from nonischemic control area or from nonischemic control hearts to the different vasodilators were not influenced by sepiapterin or methyltetrahydropterin. Additionally, treatment of control vessels with 2,4-diamino-6-hydroxypyrinidine, an inhibitor of GTP cyclohydrolase I, the rate-limiting enzyme in the synthesis of tetrahydrobiopterin, significantly attenuated the effect of the endothelium-dependent vasodilators but not the effect of the endothelium-independent agonist (33).
In a similar way, substitution with sepiapterin acutely improved the reduction of vasodilation to the endothelium-dependent agonists in coronary arterioles from both humans and pigs with atherosclerosis. Sepiapterin had no such effect on the responsiveness of vessels from nonatherosclerotic control subjects (34).
These findings confirm the hypothesis that a reduced availability of tetrahydrobiopterin leading to an imbalance of intracellular levels of NO on one side and toxic radicals on the other side is involved in the development of endothelial dysfunction in different vascular pathologies.
| |
CLINICAL DATA |
|---|
|
TOP
INTRODUCTION
BIOCHEMICAL AND CELL CULTURE...
DATA FROM EXPERIMENTS IN...
CLINICAL DATA
CONCLUSIONS
REFERENCES
|
|---|
In a clinical study, the hypothesis was followed that
tetrahydrobiopterin deficiency contributes to the decreased
activity of NO observed in patients with hypercholesterolemia
(31). To test this hypothesis,
N
-monomethyl-L-arginine
(L-NMMA, inhibitor of basal NO activity), serotonin
(endothelium-dependent vasodilator), and nitroprusside (endothelium-independent vasodilator) were infused into the brachial artery of patients with and without hypercholesterolemia before and
after coinfusion with L-arginine or
tetrahydrobiopterin, or a combination of both. Infusion of
tetrahydrobiopterin led to a significant improvement of both the
attenuation of L-NMMA-induced vasoconstriction and the
reduction of serotonin-induced vasodilation in the hypercholesteremic
patients. In contrast, tetrahydrobiopterin infusion had no effect in
control patients without hypercholesteremia. The authors concluded that
decreased vasodilation to serotonin in hypercholesteremic subjects is
due to a reduced activity of NO secondary to an altered availability of tetrahydrobiopterin.
Similar results could be obtained in another clinical study in which the effect of tetrahydrobiopterin supplementation on endothelium-dependent vasodilation in smokers was investigated (10). Infusion with tetrahydrobiopterin significantly improved the decreased response of the brachial artery of smokers to endothelium-dependent dilators but not to an endothelium-independent agonist.
Recently, these observation could be reproduced in the coronary circulation (18). The authors found that coronary flow responses in humans with coronary artery disease can significantly be improved by application of tetrahydrobiopterin.
| |
CONCLUSIONS |
|---|
|
TOP
INTRODUCTION
BIOCHEMICAL AND CELL CULTURE...
DATA FROM EXPERIMENTS IN...
CLINICAL DATA
CONCLUSIONS
REFERENCES
|
|---|
The phenomenon of endothelial dysfunction has been described in different pathophysiological conditions. It can therefore be assumed that endothelial dysfunction is a generalized response of vessels to a variety of injuries. As the result of several clinical studies, it has become evident that endothelial dysfunction is of prognostic significance, for example, for patients with coronary artery disease regarding the rate of cardiac events (26). Nevertheless, there remains a lot of speculation with respect to the significance of endothelial dysfunction. To date, there are no large clinical trials demonstrating that treatment of endothelial dysfunction improves the prognosis. Furthermore, it is unknown which therapy is most effective, most safe, and most cost effective. On the basis of the available data, possible treatment options include angiotensin-converting enzyme inhibitors, statins, radical scavenging substances such as vitamin E, L-arginine, and tetrahydrobiopterin. These substances have been shown to improve endothelial dysfunction via different mechanisms, finally increasing the availability of NO and decreasing the presence of toxic radicals (4, 14, 34, 39). However, there are still controversies that need to be resolved. For example, whereas treatment with statins has been found to improve the prognosis of patients with coronary artery disease in some studies (24, 25), there is a recent study demonstrating that, although endothelial dysfunction is attenuated by statins, there is no impact on the prognosis (39).
From the theoretical background and the very fundamental data demonstrating the important role of tetrahydrobiopterin for the synthesis of NO and for the regulation of the NO-producing enzyme NO synthase, a manipulation of the metabolism of tetrahydrobiopterin may be promising with regard to the treatment of endothelial dysfunction in the future.
| |
ACKNOWLEDGEMENTS |
|---|
This paper was supported in part by a grant from the Deutsche Forschungsgemeinschaft.
| |
FOOTNOTES |
|---|
Address for reprint requests and other correspondence: C. P. Tiefenbacher, Dept. of Cardiology, Univ. of Heidelberg, Bergheimerstrasse 58, 69115 Heidelberg, Germany (E-mail: ctiefenbacher{at}med.uni-heidelberg.de).
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
| |
REFERENCES |
|---|
|
TOP
INTRODUCTION
BIOCHEMICAL AND CELL CULTURE...
DATA FROM EXPERIMENTS IN...
CLINICAL DATA
CONCLUSIONS
REFERENCES
|
|---|
1.
Chilian, WM,
Dellsperger KC,
Layne SM,
Eastham CL,
Armstrong MA,
Marcus ML,
and
Heistad DD.
Effects of atherosclerosis on the coronary microcirculation.
Am J Physiol Heart Circ Physiol
27:
H529-H539,
1990.
2.
Cosentino, F,
and
Katusic ZS.
Tetrahydrobiopterin and dysfunction of endothelial nitric oxide synthase in coronary arteries.
Circulation
91:
139-144,
1995
3.
Cosentino, F,
and
Lüscher TF.
Tetrahydrobiopterin and endothelial nitric oxide synthase activity.
Cardiovasc Res
43:
274-278,
1999
4.
Drexler, H,
Zeiher AM,
Meinzer K,
and
Just H.
Correction of endothelial dysfunction in coronary microcirculation of hypercholesterolaemic patients by L-arginine.
Lancet
338:
1546-1550,
1991[Web of Science][Medline].
5.
Felmayer-Werner, G,
Werner ER,
Fuchs D,
Hausen A,
Reibnegger G,
Schmidt K,
Weiss G,
and
Wachter H.
Pteridine biosynthesis in human endothelial cells.
J Biol Chem
268:
1842-1846,
1993
6.
Fichtlscherer, S,
Rosenberger G,
Walter DH,
Breuer S,
Dimmeler S,
and
Zeiher AM.
Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease.
Circulation
102:
1000-1006,
2000
7.
Furchgott, R,
and
Zawadzki JV.
The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine.
Nature
299:
373-376,
1980.
8.
Gross, SS,
and
Levi R.
Tetrahydrobiopterin synthesis: an absolute requirement for cytokine-induced nitric oxide generation by vascular smooth muscle.
J Biol Chem
267:
25722-25729,
1992
9.
Heinzel, B,
Klatt JM,
EBöhme,
and
Mayer B.
Ca2+/calmodulin-dependent formation of hydrogen peroxide by brain nitric oxide synthase.
Biochem J
281:
627-630,
1993.
10.
Heitzer, T,
and
Munzel T.
The cofactor of nitric oxide synthase tetrahydrobiopterin improves endothelial function in smokers.
Circulation
98:
I-735,
1998.
11.
Hevel, JM,
and
Marletta MA.
Macrophage nitric oxide synthase: relationship between enzyme-bound tetrahydrobiopterin and synthase activity.
Biochemistry
31:
7160-7165,
1992[Medline].
12.
Hingorani, AD,
Cross J,
Kharbanda RK,
Mullen MJ,
Bhagat K,
Taylor M,
Donlad AE,
Palacios M,
Griffin GE,
Deanfield JE,
MacAllister RJ,
and
Vallance P.
Acute systemic inflammation impairs endothelium-dependent dilatation in humans.
Circulation
102:
994-999,
2000
13.
Ishii, M,
Shimizu S,
Momose K,
and
Yamamoto T.
SIN-1-induced cytotoxicity in cultured endothelial cells involves reactive oxygen species and nitric oxide: protective effect of sepiapterin.
J Cardiovasc Pharmacol
33:
295-300,
1999[Web of Science][Medline].
14.
Kaufmann, PA,
Gnecchi-Ruscone T,
di Terlizzi M,
Schäfers KP,
Lüscher TF,
and
Camici PG.
Coronary heart disease in smokers: vitamin C restores coronary microcirculatory function.
Circulation
102:
1233-1238,
2000
15.
Kobayashi, K,
and
Miki M.
A direct demonstration of reaction of nitric oxide with superoxide anion by the use of pulse radiolysis.
In: Frontiers of Reactive Oxygen Species in Biology & Medicine, edited by Asada K,
and Yoshikawa T.. Amsterdam, The Netherlands: Elsevier Science, 1994, p. 223-224.
16.
Kuo, L,
Davis MJ,
Cannon S,
and
Chilian WM.
Pathophysiological consequences of atherosclerosis extend into the coronary microcirculation. Restoration of endothelium-dependent responses by L-arginine.
Circ Res
70:
465-476,
1992
17.
Mayer, B,
and
Werner ER.
In search of a function for tetrahydrobiopterin in the biosynthesis of nitric oxide.
Naunyn Schmiedebergs Arch Pharmacol
351:
453-463,
1995[Web of Science][Medline].
18.
Mayer, W,
Cosentino F,
Lutolf RB,
Fleisch M,
Seiler C,
Hess OM,
Meier B,
and
Luscher TF.
Tetrahydrobiopterin improves endothelial function in patients with coronary artery disease.
J Cardiovasc Pharmacol
35:
173-178,
2000[Web of Science][Medline].
19.
Meininger, CJ,
Marinos RS,
Hatakeyama K,
Martinez-Zaguilan R,
Rojas JD,
Kelly KA,
and
Wu G.
Impaired nitric oxide production in coronary endothelial cells of the spontaneously diabetic BB rat is due to tetrahydrobiopterin deficiency.
Biochem J
349:
353-356,
2000[Web of Science][Medline].
20.
Milstien, S,
and
Katusic Z.
Oxidation of tetrahydrobiopterin by peroxynitrite: implications for vascular endothelial function.
Biochem Biophys Res Commun
263:
681-684,
1999[Web of Science][Medline].
21.
Nichol, CA,
Smith GK,
and
Duch DS.
Biosynthesis and metabolism of tetrahydrobiopterin and molybdopterin.
Annu Rev Biochem
54:
729-764,
1985[Web of Science][Medline].
22.
Ohara, Y,
Peterson TE,
and
Harrison DG.
Hypercholesteremia increases endothelial superoxide anion production.
J Clin Invest
91:
2546-2551,
1993.
23.
Palmer, RMJ,
Ferrige AG,
and
Moncada S.
Nitric oxide release accounts for the biological acticity of endothelial-derived relaxing factor.
Nature
327:
534-536,
1987.
24.
Pitt, B,
Waters D,
Brown WV,
van Boven AJ,
Schwartz L,
Title LM,
Eisenberg D,
Shurzinske L,
and
McCormick LS.
Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin Versus Revascularization Treatment Investigators.
N Engl J Med
341:
70-76,
1999
25.
Sacks, FM,
Pfeffer MA,
Moye LA,
Rouleau JL,
Rutherford JD,
Cole TG,
Brown L,
Warnica JW,
Arnold JM,
Wun CC,
Davis BR,
and
Braunwald E.
The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels.
N Engl J Med
335:
1001-1009,
1996
26.
Schächinger, V,
Britten M,
and
Zeiher AM.
Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease.
Circulation
101:
1899-1906,
2000
27.
Schmidt, HHHW,
Hofmann H,
Schindler U,
Shutenko ZA,
Cunningham DD,
and
Feelisch M.
No NO from NO synthase.
Proc Natl Acad Sci USA
93:
14492-14497,
1996
28.
Schoedon, G,
Schneemann M,
Hofer S,
Guerrero L,
Blau N,
and
Schaffner A.
Regulation of the L-arginine-dependent and tetrahydrobiopterin-dependent biosynthesis of nitric oxide in murine macrophages.
Eur J Biochem
213:
833-839,
1993[Web of Science][Medline].
29.
Scott-Burden, T.
Regulation of nitric oxide production by tetrahydrobiopterin (Editorial).
Circulation
91:
248-250,
1995
30.
Shimokawa, H,
and
Vanhoutte PM.
Dietary cod liver oil improves endothelium-dependent responses in hypercholesteremic and atherosclerotic porcine coronary arteries.
Circulation
78:
1421-1430,
1988
31.
Stroes, E,
Kastelein J,
Cosentino F,
Erkelens W,
Wever R,
Koomans H,
Luscher T,
and
Rabelink T.
Tetrahydrobiopterin restores endothelial function in hypercholesterolemia.
J Clin Invest
99:
41-46,
1997[Web of Science][Medline].
32.
Stroes, E,
Hijimering M,
van Zandvoort M,
Wever R,
Rabelink TJ,
and
van Faassen EE.
Origin of superoxide production by endothelial nitric oxide synthase.
FEBS Lett
438:
161-164,
1998[Web of Science][Medline].
33.
Tiefenbacher, CP,
Chilian WM,
Mitchell M,
and
Defily DV.
Restoration of endothelium-dependent vasodilation after reperfusion injury by tetrahydrobiopterin.
Circulation
94:
1423-1429,
1996
34.
Tiefenbacher, CP,
Bleeke T,
Vahl C,
Amann K,
Vogt A,
and
WKübler
Endothelial dysfunction of coronary resistance arteries is improved by tetrahydrobiopterin in atherosclerosis.
Circulation
102:
2172-2179,
2000
35.
Ting, HH,
Timimi FK,
Boles KS,
Creager SJ,
Ganz P,
and
Creager MA.
Vitamin C improves endothelium-dependent vasodilation in patients with non-insulin-dependent diabetes mellitus.
J Clin Invest
97:
22-28,
1996[Web of Science][Medline].
36.
Vasquez Vivar, J,
Kalyanamaran B,
Martasek P,
Hogg N,
Siler Master BS,
Karoui H,
Tordos P,
and
Pritchard KA, Jr.
Superoxide generation by endothelial nitric oxide synthase: The influence of cofactors.
Proc Natl Acad Sci USA
95:
9220-9225,
1998
37.
Vasquez Vivar, JM,
Martasek P,
and
Kalyanaraman B.
BH4/BH2 ratio but not ascorbate controls superoxide and nitric oxide generation by eNOS (Abstract).
Circulation
102:
II-63,
2000.
38.
Vinten Johansen, J,
Zhao ZQ,
Nakamura M,
Jordan JE,
Ronson RS,
Thourani VH,
and
Guyton RA.
Nitric oxide and the vascular endothelium in myocardial ischemia-reperfusion injury.
Ann NY Acad Sci
874:
354-370,
1999[Web of Science][Medline].
39.
Vita, JA,
Yeung AC,
Winniford M,
Hodgson JM,
Treasure CB,
Klein JL,
Werns S,
Kern M,
Plotkin D,
Shih J,
Mitchel Y,
and
Ganz P.
Effect of cholesterol-lowering therapy on coronary endothelial vasomotor function in patients with coronary artery disease.
Circulation
102:
846,
2000
40.
Zeiher, AM,
Drexler H,
Saurbier B,
and
Just H.
Endothelium-mediated coronary blood flow modulation in humans. Effects of age, atherosclerosis, hypercholesterolemia, and hypertension.
J Clin Invest
92:
652-662,
1993.
This article has been cited by other articles:
|
|
 |
|
  R. Siekmeier, T. Grammer, and W. Marz Roles of Oxidants, Nitric Oxide, and Asymmetric Dimethylarginine in Endothelial Function Journal of Cardiovascular Pharmacology and Therapeutics, December 1, 2008; 13(4): 279 - 297. [Abstract] [PDF]
|
|
|
|
 |
|
 M. D. Delp, B. J. Behnke, S. A. Spier, G. Wu, and J. M. Muller-Delp Ageing diminishes endothelium-dependent vasodilatation and tetrahydrobiopterin content in rat skeletal muscle arterioles J. Physiol., February 15, 2008; 586(4): 1161 - 1168. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-M. Li and A. M Shah Endothelial cell superoxide generation: regulation and relevance for cardiovascular pathophysiology Am J Physiol Regulatory Integrative Comp Physiol, November 1, 2004; 287(5): R1014 - R1030. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Kawashima and M. Yokoyama Dysfunction of Endothelial Nitric Oxide Synthase and Atherosclerosis Arterioscler. Thromb. Vasc. Biol., June 1, 2004; 24(6): 998 - 1005. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. R. Werner, A. C.F. Gorren, R. Heller, G. Werner-Felmayer, and B. Mayer Tetrahydrobiopterin and Nitric Oxide: Mechanistic and Pharmacological Aspects Experimental Biology and Medicine, December 1, 2003; 228(11): 1291 - 1302. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Malo, F. Desjardins, J.-F. Tanguay, J.-C. Tardif, M. Carrier, and L. P. Perrault Tetrahydrobiopterin and antioxidants reverse the coronary endothelial dysfunction associated with left ventricular hypertrophy in a porcine model Cardiovasc Res, August 1, 2003; 59(2): 501 - 511. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. J. Woo, J. Y. Kang, Y. K. Choi, and Y. S. Park Production of Sepiapterin in Escherichia coli by Coexpression of Cyanobacterial GTP Cyclohydrolase I and Human 6-Pyruvoyltetrahydropterin Synthase Appl. Envir. Microbiol., June 1, 2002; 68(6): 3138 - 3140. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Verma and T. J. Anderson Fundamentals of Endothelial Function for the Clinical Cardiologist Circulation, February 5, 2002; 105(5): 546 - 549. [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |
) from O